Sort
30,917 grants matching “tumor microenvironment”
Mechanisms of neuroinflammation in brain metastasis progression
$373,843Siyuan Zhang · University Of Notre Dame · R01 · FY2021 · CA
In Vivo Genetic Analysis of Compartmentalized Cell Elimination
$373,823Piya Ghose · University Of Texas Arlington · R35 · FY2025 · GM
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$373,817Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2021 · AG
Distinct Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches
$373,783Keith Syson Chan · Methodist Hospital Research Institute · R01 · FY2024 · CA
Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug Resistance
$373,778Michaela R. Reagan · Mainehealth · R37 · FY2024 · CA
Targeting cellular double-stranded RNA homeostasis in breast cancer
$373,774Cecil Han · Georgetown University · R01 · FY2021 · CA
Targeting cellular double-stranded RNA homeostasis in breast cancer
$373,774Cecil Han · Georgetown University · R01 · FY2022 · CA
Targeting cellular double-stranded RNA homeostasis in breast cancer
$373,774Cecil Han · Georgetown University · R01 · FY2025 · CA
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
$373,718Abraham P Lee · University Of California-Irvine · R33 · FY2023 · CA
Regulation of repetitive elements in cancer by P53 and epigenetic mechanisms
$373,701Katherine B Chiappinelli · George Washington University · R37 · FY2022 · CA
Clinical Significance and Mechanism of Action of Exosomal microRNAs in Neuroblastoma chemoresistance
$373,701Muller Fabbri · Children'S Research Institute · R01 · FY2022 · CA
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
$373,697Everett Stone · University Of Texas At Austin · R01 · FY2019 · CA
Influence of hemodynamic shear stress on circulating tumor cells
$373,671Michael D. Henry · University Of Iowa · R01 · FY2022 · CA
Core C: Biospecimen, Pathology, and Genomics Core
$373,653David L Rimm · Yale University · P50 · FY2022 · CA
Reprogramming myeloid cells to inhibit cancer development
$373,643Chengcheng Zhang · Ut Southwestern Medical Center · R01 · FY2025 · CA
MRI Characterization of Biological Risk of Ductal Carcinoma in Situ
$373,640Habibollah Rahbar · University Of Washington · R01 · FY2019 · CA
Projecdt 3 - Modulation of bone environment to enhance response of bone cancers
$373,605John F Dipersio · Washington University · U54 · FY2018 · CA
Regulation of Tumor Microenvironment in Cancer
$373,604Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2015 · CA
Defining the determinants of response and resistance to therapy for Richter's Syndrome
$373,544Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2021 · CA
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
$373,520Rumela Chakrabarti · University Of Pennsylvania · R01 · FY2020 · CA
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$373,461Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2021 · AG
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
$373,424Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2025 · NS
Injectable Hybrid SMART spheroids to enhance stem cell therapy for CNS injuries
$373,413Kibum Lee · Rutgers, The State Univ Of N.J. · R01 · FY2024 · NS
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
$373,399Margaret A Shipp · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
$373,399Margaret A Shipp · Dana-Farber Cancer Inst · R01 · FY2017 · CA